BioSpace News Archive

Baudax Bio, Inc. announced the closing of its previously announced public offering of an aggregate of 3,478,262 shares of its common stock, together with accompanying common stock purchase warrants, at a public offering price of $1.15 per share and accompanying warrants.

ZyVersa Therapeutics, Inc. announces closing on April 28, 2023 of its previously announced “reasonable best efforts” public offering of 11,015,500 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,015,500 shares of common stock at an effective combined price of $1.00 per share and common warrant for aggregate gross proceeds of approximately $11.0 million, before deducting placement agent fees and other offering expenses.

Blood Advances, part of leading hematology journal Blood, also a Journal of the American Society of Hematology, recently published the clinical study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL) patients.

OpGen, Inc. today announced the pricing of a public offering of an aggregate of 4,495,825 shares of its common stock (or pre-funded warrants in lieu thereof) and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share (or pre-funded warrant in lieu thereof) and accompanying warrant.

Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announced the financial results for its fourth quarter and fiscal year ending December 31, 2022.

Exactech announced that a new study1 that shows positive two-year outcomes for the Equinoxe® Humeral Reconstruction Prosthesis, a solution for extensive proximal humerus bone loss, has just been published in the Journal of Shoulder and Elbow Surgery.

BVI, a diversified global ophthalmic device company, today announced it has completed enrollment of its U.S. Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal intraocular lens (IOL), FINEVISION® HP.

Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, announced at the recent HIMSS Conference a new agreement with Roche, which will allow for EarlySign ColonFlag to be offered within the navify® Algorithm Suite from Roche Diagnostics.

The Midwest Bioprocessing Center (MBC) and McKinley Resources are pleased to announce a distribution partnership surrounding MBC’s FeruliShield™ feruloyl glycerides ingredients for cosmetics and personal care applications. Under the agreement McKinley will be the exclusive distribution partner for FeruliShield™ products in North America.

Urotronic, Inc. today announced the presentation of positive data from two clinical trials evaluating the Optilume® BPH System’s effectiveness and durability in treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).